NasdaqGS:OSUR

Stock Analysis Report

Executive Summary

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.

Snowflake

Fundamentals

Flawless balance sheet with acceptable track record.

Risks

  • OraSure Technologies has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has OraSure Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.3%

NasdaqGS:OSUR

1.9%

US Medical Equipment

2.1%

US Market


1 Year Return

-56.5%

NasdaqGS:OSUR

13.6%

US Medical Equipment

-0.04%

US Market

OSUR underperformed the Medical Equipment industry which returned 14% over the past year.

OSUR underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

OSURIndustryMarket
7 Day-0.3%1.9%2.1%
30 Day-17.1%-0.2%-3.2%
90 Day-13.3%10.2%2.8%
1 Year-56.5%-56.5%14.5%13.6%2.2%-0.04%
3 Year-8.2%-8.2%70.2%65.0%41.5%32.3%
5 Year-13.8%-13.8%133.6%106.8%55.0%37.8%

Price Volatility Vs. Market

How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OraSure Technologies undervalued based on future cash flows and its price relative to the stock market?

13%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

OraSure Technologies's share price is below the future cash flow value, but not at a moderate discount (< 20%).

OraSure Technologies's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

OraSure Technologies is good value based on earnings compared to the US Medical Equipment industry average.

OraSure Technologies is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

OraSure Technologies is poor value based on expected growth next year.


Price Based on Value of Assets

OraSure Technologies is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is OraSure Technologies expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

16.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

OraSure Technologies's revenue is expected to grow by 6.7% yearly, however this is not considered high growth (20% yearly).

OraSure Technologies's earnings are expected to grow by 16.2% yearly, however this is not considered high growth (20% yearly).

OraSure Technologies's revenue growth is positive but not above the United States of America market average.

OraSure Technologies's earnings growth is expected to exceed the United States of America market average.

OraSure Technologies's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if OraSure Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has OraSure Technologies performed over the past 5 years?

35.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

OraSure Technologies has delivered over 20% year on year earnings growth in the past 5 years.

OraSure Technologies's 1-year earnings growth is less than its 5-year average (29.5% vs 35%)

OraSure Technologies's earnings growth has exceeded the US Medical Equipment industry average in the past year (29.5% vs 28.9%).


Return on Equity

OraSure Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

OraSure Technologies used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

OraSure Technologies has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is OraSure Technologies's financial position?


Financial Position Analysis

OraSure Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

OraSure Technologies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

OraSure Technologies has no debt.

OraSure Technologies has not taken on any debt in the past 5 years.

OraSure Technologies has no debt, it does not need to be covered by operating cash flow.

OraSure Technologies has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

OraSure Technologies has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is OraSure Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate OraSure Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate OraSure Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as OraSure Technologies has not reported any payouts.

Unable to verify if OraSure Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as OraSure Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of OraSure Technologies's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Steve Tang (58yo)

1.3yrs

Tenure

US$2,099,594

Compensation

Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre ...


CEO Compensation Analysis

Steve's remuneration is about average for companies of similar size in United States of America.

Steve's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.0yrs

Average Tenure

58yo

Average Age

The tenure for the OraSure Technologies management team is about average.


Board Age and Tenure

3.4yrs

Average Tenure

59yo

Average Age

The tenure for the OraSure Technologies board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$8,56014 May 19
Stephen Tang
EntityIndividual
Role
Chief Executive Officer
President
Shares1,000
Max PriceUS$8.56
BuyUS$85,48714 May 19
Jack Jerrett
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares10,000
Max PriceUS$8.55
BuyUS$90,31414 May 19
Roberto Cuca
EntityIndividual
Role
Chief Financial Officer
CFO & Principal Accounting Officer
Shares10,000
Max PriceUS$9.04
SellUS$130,32029 Aug 18
Charles Patrick
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,000
Max PriceUS$16.29

Ownership Breakdown


Management Team

  • Steve Tang (58yo)

    President

    • Tenure: 1.3yrs
    • Compensation: US$2.10m
  • Jack Jerrett (60yo)

    Senior VP

    • Tenure: 18.8yrs
    • Compensation: US$973.46k
  • Roberto Cuca (51yo)

    CFO & Principal Accounting Officer

    • Tenure: 1.2yrs
    • Compensation: US$1.05m
  • Brian Smith (60yo)

    Vice Chairman & EVP of Innovation - DNA Genotek

    • Tenure: 2.0yrs
    • Compensation: US$978.65k
  • David Rappaport

    Senior Vice President of Business Development

    • Tenure: 1.3yrs
  • Nancy McLane

    Senior Vice President of Operations

    • Tenure: 0.0yrs
  • Jeanne Mell

    Vice President of Corporate Communications

    • Tenure: 1.0yrs
  • Tony Zezzo (65yo)

    Executive VP & Business Unit Leader of Infectious Disease

    • Tenure: 2.6yrs
    • Compensation: US$1.06m
  • Kathy Weber (52yo)

    Executive VP & Business Unit Leader of Molecular Solutions

    • Tenure: 6.8yrs
  • Mike Reed (50yo)

    Senior VP of R&D and Chief Science Officer

    • Tenure: 3.3yrs
    • Compensation: US$778.96k

Board Members

  • Chuck Patrick (64yo)

    Independent Director

    • Tenure: 13.6yrs
    • Compensation: US$168.99k
  • Eamonn Hobbs (60yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$157.24k
  • Steve Tang (58yo)

    President

    • Tenure: 1.3yrs
    • Compensation: US$2.10m
  • Ronny Lancaster (67yo)

    Independent Director

    • Tenure: 16.3yrs
    • Compensation: US$169.74k
  • Mike Celano (60yo)

    Chairman of the Board

    • Tenure: 1.3yrs
    • Compensation: US$506.36k
  • James Datin (56yo)

    Director

    • Tenure: 0.0yrs
  • Mara Aspinall (57yo)

    Independent Director

    • Tenure: 2.2yrs
    • Compensation: US$157.24k
  • Aradhana Sarin (44yo)

    Independent Director

    • Tenure: 1.5yrs
    • Compensation: US$562.31k

Company Information

OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OraSure Technologies, Inc.
  • Ticker: OSUR
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$439.481m
  • Shares outstanding: 61.72m
  • Website: https://www.orasure.com

Number of Employees


Location

  • OraSure Technologies, Inc.
  • 220 East First Street
  • Bethlehem
  • Pennsylvania
  • 18015
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSURNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1986
EP3DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1986

Biography

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and inter ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 23:41
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.